Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ReGen Therapeutics (ReGen), a company into the development of Colostrinin, a proline-rich polypeptide complex derived from mammalian colostrum, said that its Turkish licensee Eczacibasi Ilac Pazarlama (Eczacibasi) has received final approval to market ReGen's nutritional supplement Colostrinin in the Republic of Turkey.
Subscribe to our email newsletter
ReGen Therapeutics said that in in-vitro studies Colostrinin has been shown to prevent the aggregation of beta-amyloid and reduce it’s toxicity to cells. Colostrinin has also been shown to protect cells from oxidative stress another of the pathologies implicated in Alzheimer’s disease. In in-vivo studies Colostrinin has been shown to improve memory performance of aged rats in the Morris water maze test.
The approval now triggers a $50,000 payment to ReGen. Eczacibasi has placed an order with ReGen for a launch stock of blistered tablets for which ReGen is expected to receive a fee for the active ingredient component. These will be packaged locally by Eczacibasi under the brand-name ‘Dyna’ with product launch intended in May.
The announcement comes only a week after ReGen reported that Colostrinin is expected to be launched in India during the second quarter of 2010.